These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1214 related items for PubMed ID: 30058841

  • 1. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A, Ruscica M, Ferri N.
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS.
    Circulation; 2018 Jul 10; 138(2):131-140. PubMed ID: 29530884
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V.
    Circulation; 2016 Nov 29; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract] [Full Text] [Related]

  • 10. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F, Dal Pino B, Bigazzi F, Ripoli A, Passino C, Gabutti A, Pasanisi EM, Petersen C, Valleggi A, Todiere G, Barison A, Giannoni A, Panchetti L, Becherini F, Pianelli M, Luciani R, Sampietro T.
    Eur J Prev Cardiol; 2017 Sep 29; 24(14):1528-1531. PubMed ID: 28555526
    [Abstract] [Full Text] [Related]

  • 11. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP.
    Atherosclerosis; 2019 Sep 29; 288():194-202. PubMed ID: 31253441
    [Abstract] [Full Text] [Related]

  • 12. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, Domenger C, Letierce A, Israel M, Samuel R, Del Prato S.
    Cardiovasc Diabetol; 2020 Feb 08; 19(1):14. PubMed ID: 32035487
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA.
    Cardiovasc Diabetol; 2019 Nov 09; 18(1):149. PubMed ID: 31706300
    [Abstract] [Full Text] [Related]

  • 15. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov 09; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 16. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors.
    Alali RA.
    Rev Cardiovasc Med; 2019 Mar 30; 20(1):1-8. PubMed ID: 31184090
    [Abstract] [Full Text] [Related]

  • 17. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG.
    J Am Heart Assoc; 2017 Oct 02; 6(10):. PubMed ID: 28971955
    [Abstract] [Full Text] [Related]

  • 18. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May 02; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
    Nam CW, Kim DS, Li J, Baccara-Dinet MT, Li I, Kim JH, Kim CJ.
    Korean J Intern Med; 2019 Nov 02; 34(6):1252-1262. PubMed ID: 30257549
    [Abstract] [Full Text] [Related]

  • 20. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V, Glueck CJ, Lee K, Goldenberg N, Prince M, Kumar A, Goldenberg M, Anand I, Wang P.
    Vasc Health Risk Manag; 2017 Nov 02; 13():247-253. PubMed ID: 28740397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.